Surgeon recommends firms manufacture IOLs in 0.25 D steps

Article

It would be helpful if IOL manufacturers made lenses available in 0.25 D steps and provided more detailed information regarding the optical design since refractive outcomes can now be predicted more accurately.

It would be helpful if IOL manufacturers made lenses available in 0.25 D steps and provided more detailed information regarding the optical design since refractive outcomes can now be predicted more accurately, according to Thomas Olsen from the University Eye Clinic, Aarhus Hospital, Denmark.

Dr Olsen obtained the refractive results from several thousand IOL implantations using optical biometry and compared them with the predictions made using regression methods, thick lens vergence methods and exact ray tracing methods. In each case the predictions were based on previously described true ACD-prediction algorithms.

It was discovered that thick lens vergence and exact ray tracing methods are more effective than regression methods and that refractive outcomes can be predicted accurately well below 0.5 D, which is the current power availability step.

The results indicate that it would be useful if IOLs were available in 0.25 D steps.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.